ARWR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARWR's Piotroski F-Score of 4/9 indicates weak financial health, with a notable debt/equity ratio of 1.24 and a lack of Altman Z-Score data, raising concerns about long-term solvency. However, the company exhibits exceptional profitability with a 75.5% ROE and 100% gross margin, supported by a staggering 10,461% YoY revenue growth. Despite a high current price of $55.05 and elevated valuation multiples (P/E: 34.41, P/S: 7.07), the stock trades at a premium due to explosive growth expectations. Analysts maintain a 'buy' consensus with a target price of $81.36, reflecting strong conviction in future upside. Insider selling activity, while bearish in sentiment, may reflect liquidity events rather than fundamental concerns.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ARWR vs LLY: Head-to-Head Comparison
This page compares Arrowhead Pharmaceuticals, Inc. (ARWR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.